ADMA (admabiologics.com) יחס שווי שוק לשווי בספרים

ADMA Biologics (ADMA) is a niche biopharmaceutical business that develops antibodies for individuals with immune deficiencies and infections, maintaining full control over the plasma processing cycle. Current price action reflects a period in which the company has achieved excess liquidity and high operating profit, with its key metric standing at 6.08. Growth is driven by the expansion of therapeutic applications for its core products and the ownership of its own raw material collection network.

High costs of maintaining a specialized cold chain for plasma transportation directly impact the asset structure of ADMA Biologics (ADMA). This P/BV ratio reflects the relationship between the business's market value and its net book assets, allowing investors to assess the premium paid for capital by analyzing the trends on this chart.